Dose-dependent inhibition of the CYP2D6 catalyzed oxidation of sparteine by mepyramine in healthy volunteers

Pharmacology and Toxicology

Volumn 89, Issue 6, 2001, Pages 331-334

  Kortunay, Selim ^a   Bozkurt, Atila ^a   Basci, Nursabah E ^a   Brøsen, Kim ^b   Kayaalp, S Oguz ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; CHLORPHENIRAMINE; CLEMASTINE FUMARATE; CYTOCHROME P450 2D6; MEPYRAMINE; SPARTEINE SULFATE;

ARTICLE; CATALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EXCRETION; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-ARRHYTHMIA AGENTS; CATALYSIS; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; HISTAMINE H1 ANTAGONISTS; HUMANS; OXIDATION-REDUCTION; PYRILAMINE; SPARTEINE;

EID: 0035652116     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2001.d01-170.x     Document Type: Article

References (3)

1. Alhaide, A. A. & A. A. Mustafa: Acceleration of rat brain beta-adrenoceptor subsensitivity following the coadministration of histamine receptor antagonists with imipramine. Agents Actions 1989, 28, 153-158.
2. Bozkurt, A., N. E. Basci, A. Isimer, A. Sayal & S. O. Kayaalp: Polymorphic debrisoquine metabolism in a Turkish population. Clin. Pharmacol. Tlier. 1994, 55, 399-401.
3. Brosen, K. & L. E Gram: Clinical significance of the sparteine/ debrisoquine oxidation polymorphism. Eitr. J. Clin. Pharmacol. 1989, 36, 537-547.